company background image
EVG

Evgen PharmaAIM:EVG Stock Report

Market Cap

UK£15.5m

7D

-1.6%

1Y

-35.1%

Updated

01 Dec, 2021

Data

Company Financials +
EVG fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

EVG Stock Overview

Evgen Pharma plc, a clinical stage drug development company, focuses in the development of sulforaphane-based compunds for the treatment of multiple diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Evgen Pharma
Historical stock prices
Current Share PriceUK£0.057
52 Week HighUK£0.13
52 Week LowUK£0.042
Beta1.53
1 Month Change-0.88%
3 Month Change-19.29%
1 Year Change-35.06%
3 Year Change-67.71%
5 Year Change-75.96%
Change since IPO-83.91%

Recent News & Updates

Nov 24
We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Aug 06
Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

EVGGB BiotechsGB Market
7D-1.6%-2.4%-2.6%
1Y-35.1%22.5%10.9%

Return vs Industry: EVG underperformed the UK Biotechs industry which returned 22.5% over the past year.

Return vs Market: EVG underperformed the UK Market which returned 10.9% over the past year.

Price Volatility

Is EVG's price volatile compared to industry and market?
EVG volatility
EVG Average Weekly Movement6.3%
Biotechs Industry Average Movement5.9%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.8%
10% least volatile stocks in GB Market2.5%

Stable Share Price: EVG is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: EVG's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20078Huw Joneshttps://evgen.com

Evgen Pharma plc, a clinical stage drug development company, focuses in the development of sulforaphane-based compunds for the treatment of multiple diseases. Its core technology is Sulforadex, a means of synthesizing and stabilizing the naturally occurring compound sulforaphane. The company’s lead product is SFX-01, a synthetic and stabilized form of sulforaphane that is in Phase II clinical trials for the treatment of metastatic breast cancer; in preclinical stage for glioma and glioblastoma; and in Phase IIb for treating acute respiratory infections.

Evgen Pharma Fundamentals Summary

How do Evgen Pharma's earnings and revenue compare to its market cap?
EVG fundamental statistics
Market CapUK£15.53m
Earnings (TTM)-UK£2.67m
Revenue (TTM)UK£194.00k

80.7x

P/S Ratio

-5.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EVG income statement (TTM)
RevenueUK£194.00k
Cost of RevenueUK£3.39m
Gross Profit-UK£3.19m
Expenses-UK£521.00k
Earnings-UK£2.67m

Last Reported Earnings

Mar 31, 2021

Next Earnings Date

Dec 07, 2021

Earnings per share (EPS)-0.0097
Gross Margin-1,646.91%
Net Profit Margin-1,378.35%
Debt/Equity Ratio0.0%

How did EVG perform over the long term?

See historical performance and comparison

Valuation

Is Evgen Pharma undervalued compared to its fair value and its price relative to the market?

1.32x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EVG's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EVG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EVG is unprofitable, so we can't compare its PE Ratio to the UK Biotechs industry average.

PE vs Market: EVG is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EVG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EVG is good value based on its PB Ratio (1.3x) compared to the GB Biotechs industry average (6.2x).


Future Growth

How is Evgen Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-33.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EVG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EVG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EVG is forecast to have no revenue next year.

High Growth Revenue: EVG is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EVG is forecast to be unprofitable in 3 years.


Past Performance

How has Evgen Pharma performed over the past 5 years?

4.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EVG is currently unprofitable.

Growing Profit Margin: EVG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EVG is unprofitable, but has reduced losses over the past 5 years at a rate of 4.8% per year.

Accelerating Growth: Unable to compare EVG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EVG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.7%).


Return on Equity

High ROE: EVG has a negative Return on Equity (-22.64%), as it is currently unprofitable.


Financial Health

How is Evgen Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: EVG's short term assets (£12.3M) exceed its short term liabilities (£607.0K).

Long Term Liabilities: EVG has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: EVG is debt free.

Reducing Debt: EVG had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EVG has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: EVG has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 9% each year.


Dividend

What is Evgen Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EVG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EVG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EVG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EVG's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Huw Jones (61 yo)

1.08yrs

Tenure

UK£224,403

Compensation

Dr. Huw Jones, BSc, Ph.D. serves as Chief Executive Officer at Evgen Pharma plc since October 1, 2020. He has been Chief Executive Officer at Chronos Therapeutics Ltd. since December 2012 and serves as its...


CEO Compensation Analysis

Compensation vs Market: Huw's total compensation ($USD298.85K) is about average for companies of similar size in the UK market ($USD322.38K).

Compensation vs Earnings: Insufficient data to compare Huw's compensation with company performance.


Leadership Team

Experienced Management: EVG's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: EVG's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 100.2%.


Top Shareholders

Company Information

Evgen Pharma plc's employee growth, exchange listings and data sources


Key Information

  • Name: Evgen Pharma plc
  • Ticker: EVG
  • Exchange: AIM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£15.531m
  • Shares outstanding: 274.89m
  • Website: https://evgen.com

Number of Employees


Location

  • Evgen Pharma plc
  • Alderley Park, Block 24
  • Suite 24G13
  • Nether Alderley
  • Cheshire
  • SK10 4TG
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/01 18:54
End of Day Share Price2021/12/01 00:00
Earnings2021/03/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.